On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...
"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at...
"You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio Welcome back to...